Common Data Models for EHR Integration in Real-World Evidence Studies

Published on 23/12/2025

Streamlining EHR Integration through Common Data Models for RWE

Electronic Health Records (EHRs) provide a vast source of real-world data (RWD), but differences in formats and terminologies across systems create integration challenges. Common Data Models (CDMs) offer a solution by providing standardized data structures that enable consistent analysis across institutions, regions, and platforms.

This guide explores how pharmaceutical professionals and clinical trial stakeholders can use CDMs to harmonize EHR data, facilitating reliable real-world evidence (RWE) generation for regulatory and scientific purposes.

Table of Contents

Why Common Data Models Are Essential:

Inconsistent EHR formats across healthcare systems hinder large-scale observational studies. CDMs solve this problem by:

Defining standard tables and fields (e.g., patient demographics, diagnoses, drug exposures)
Ensuring uniform terminologies (e.g., SNOMED CT, LOINC, RxNorm)
Enabling cross-database analytics with common logic
Supporting reproducible research through aligned metadata

Whether working on safety studies or comparative effectiveness research, CDMs improve data quality and integrity, enhancing GMP compliance when observational results are used to support regulatory filings.

Key Common Data Models Used in EHR Integration:

Here are the most widely adopted CDMs in the pharma and research community:

OMOP (Observational Medical Outcomes Partnership):
- Developed by the Observational Health Data Sciences and Informatics (OHDSI) collaborative
- Captures clinical data in a

person-centric format

Supports standardized vocabularies and cohort definitions

Sentinel Common Data Model:

Created by the U.S. FDA’s Sentinel Initiative
Focused on post-marketing safety surveillance
Includes robust privacy protections and distributed analytics

PCORnet CDM:

Developed by the Patient-Centered Outcomes Research Institute
Optimized for patient-centered outcomes and engagement studies

HL7 FHIR (Fast Healthcare Interoperability Resources):

Not a CDM in the traditional sense, but a data exchange standard
Enables real-time EHR integration via APIs
Increasingly used in dynamic RWE platforms

Steps to Implement a Common Data Model for EHR Integration:

To adopt a CDM in your real-world evidence program, follow these steps:

Choose a CDM: Based on study goals, regulatory alignment, and partner ecosystem.
Extract Data: From source EHRs in both structured and unstructured formats.
Transform and Map: Clean and normalize data using extract-transform-load (ETL) pipelines, aligning with the CDM structure.
Standardize Terminologies: Use tools like Usagi for OMOP to map local codes to global standards.
Validate Data Quality: Perform checks on completeness, consistency, and referential integrity.
Deploy Analytics Tools: Utilize cohort builders, statistical engines, and visualization dashboards compatible with the CDM.

For long-term success, integrate CDM workflows into your Pharma SOP templates for reproducibility and compliance.

Regulatory Acceptance of CDM-Based Evidence:

Global regulatory bodies increasingly recognize CDM-aligned evidence in submissions. For example:

The USFDA accepts Sentinel CDM results in drug safety monitoring.
The EMA leverages OMOP-standardized data in DARWIN EU for RWE analysis.
Health Canada encourages structured data submissions to improve review efficiency.

Maintaining traceability from original EHR sources to CDM tables is critical for regulatory audits. Align with data provenance principles to ensure integrity.

Common Challenges and Solutions in CDM Adoption:

Challenge: Mapping diverse data sources with incompatible formats
Solution: Use ETL automation tools like WhiteRabbit and RabbitInAHat (OMOP) for structured mapping
Challenge: Clinical terminologies vary by institution or country
Solution: Leverage SNOMED CT crosswalks and LOINC/RxNorm mappings
Challenge: Governance and access across multi-site collaborations
Solution: Employ federated data models or distributed queries with privacy controls

Build competency by including CDM mapping training in your Pharma Validation programs to improve internal capacity.

Case Example: OMOP CDM in Oncology RWE

In an oncology real-world evidence study, a pharmaceutical sponsor mapped EHR data from five hospitals to the OMOP CDM. They used standardized definitions to:

Identify eligible lung cancer patients
Track treatment regimens and outcomes
Evaluate progression-free survival across treatment cohorts

This enabled fast data extraction and consistent outcome definitions, accelerating the generation of real-world insights aligned with StabilityStudies.in protocols.

Best Practices for Long-Term Sustainability:

Document your ETL pipelines and update them regularly as source EHRs evolve
Use open-source CDM tools to avoid vendor lock-in
Join communities like OHDSI or PCORnet to stay updated on CDM advancements
Align with pharma regulatory compliance for traceable and auditable CDM processes
Incorporate metadata standards to improve data discoverability and reusability

CDM maturity models are emerging to guide institutions through phased adoption. Early wins in pilot projects can build momentum for wider rollouts.

Conclusion: Building RWE Infrastructure through CDMs

As the demand for high-quality real-world evidence grows, integrating EHRs using common data models becomes indispensable. CDMs provide the structure, standardization, and scalability needed to transform raw EHR data into regulatory-grade evidence.

Whether leveraging OMOP, Sentinel, PCORnet, or HL7 FHIR, success lies in methodical implementation, rigorous validation, and strategic alignment with regulatory and scientific goals. With the right approach, CDMs can unlock the full potential of EHRs for next-generation evidence generation in pharmaceuticals.